• Organizations: OKYO Pharma
OKYO's urcosimod demonstrates long-term stability for NCP
Pipeline

OKYO's urcosimod demonstrates long-term stability for NCP

With a real-world study ongoing, urcosimod’s +2.5-year shelf stability further supports a potential NDA submission for regulatory approval down the road.
OKYO Pharma seeks Fast Track designation for NCP candidate
Pipeline

OKYO Pharma seeks Fast Track designation for NCP candidate

Designation would give urcosimod (formerly OK-101) an expedited pathway to potentially become the first approved treatment for this orphan disease. 
FDA approves Okyo Pharma's IND for neuropathic corneal pain candidate
Pipeline

FDA approves Okyo Pharma's IND for neuropathic corneal pain candidate

Acceptance paves the way for phase 2 trial on OK-101, with the goal to become first FDA-approved therapy for this condition.
OKYO Pharma submits NDA for neuropathic corneal pain treatment
Pipeline

OKYO Pharma submits NDA for neuropathic corneal pain treatment

Pending FDA acceptance, phase 2 clinical trial is planned to commence in Q1 2024.
Okyo Pharma to launch real-world trial on OK-101 for NCP
Pipeline

Okyo Pharma to launch real-world trial on OK-101 for NCP

Phase 2 study is planned as part of partnership with Tufts Medical Center; follows ongoing first-in-human study of OK-101 for DED.
OKYO Pharma files IND application for DED treatment
Pipeline

OKYO Pharma files IND application for DED treatment

If OK-101 meets its primary endpoint, the timeline for a new drug application with the FDA could be accelerated.